ArticleCancer discovery2021
Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia.
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Epidemiology of Cancer in Older Adults: A Systematic Review.Current oncology reports · 2024Pooled it
- Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia.JAMA network open · 2025Trial
- Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia.JAMA network open · 2024Trial
- Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).Annals of hematology · 2026Article
- Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort.Journal of the National Cancer Institute · 2026Article
- Stratifying survival: the role of social determinants of health on AML outcomes by ELN 2022 criteria.Blood advances · 2026Article
- Article
- The global epidemiology of acute myeloid leukaemia.Nature reviews. Clinical oncology · 2026Review
- AML Disparities Across Racial Ancestry Groups: A Spotlight on the NPM1 Mutations.International journal of molecular sciences · 2026Review
- Health Disparities in Acute Myeloid Leukemia Patients Undergoing Treatment with Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2.Blood and lymphatic cancer : targets and therapy · 2026Article
- Ancestry-associated social and genomic hallmarks linked with inferior outcome in elderly acute myeloid leukemia.BMC cancer · 2025Article
- A new link in the leukemia genetic puzzle.Genes & development · 2025Review
- A Novel Approach to Prognostic Factors and Risk Stratification in Pediatric AML: Case Report and Literature Review.International journal of molecular sciences · 2025Review
- Racial and Ethnic Disparity for Cancer Mortality in General and Single-Payer Healthcare Systems in the United States.Journal of racial and ethnic health disparities · 2025Article
- Review
- Biobanking and consent to future biospecimen use among adults enrolled in SWOG trials from 2000 to 2024.Blood cancer journal · 2025Article
- Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.Blood cancer discovery · 2025Review
- Real-world treatment outcomes from a retrospective cohort of patients with acute myeloid leukemia from an urban safety net hospital.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2025Article
- Evolving racial/ethnic disparities in AML survival in the novel therapy era.Blood advances · 2025Article
- Precision medicine results from equitable representation.Bone marrow transplantation · 2025Article
Corrections and comments
- Commented on by
Authors and funding
23 authors at 5 institutions in 1 country.
Funding
Abstract
Clinical outcome of patients with acute myeloid leukemia (AML) is associated with cytogenetic and molecular factors and patient demographics (e.g., age and race). We compared survival of 25,523 non-Hispanic Black and White adults with AML using Surveillance Epidemiology and End Results (SEER) Program data and performed mutational profiling of 1,339 patients with AML treated on frontline Alliance for Clinical Trials in Oncology (Alliance) protocols. Black patients had shorter survival than White patients, both in SEER and in the setting of Alliance clinical trials. The disparity was especially pronounced in Black patients <60 years, after adjustment for socioeconomic (SEER) and molecular (Alliance) factors. Black race was an independent prognosticator of poor survival. Gene mutation profiles showed fewer
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.